Ad
ANNX Stock Quote Trading Chart Annexon Inc.
home / stock / annx / annx quote
Quote | Annexon Inc. (NASDAQ:ANNX)
| Last: | $2.41 |
|---|---|
| Change Percent: | 0.42% |
| Open: | $2.39 |
| Close: | $2.41 |
| High: | $2.435 |
| Low: | $2.31 |
| Volume: | 330,870 |
| Last Trade Date Time: | 09/22/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
ANNX Last Five Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $2.41 | $2.39 | $2.41 | $2.435 | $2.31 | 330,870 | 09-22-2023 |
| $2.4 | $2.58 | $2.4 | $2.61 | $2.39 | 304,310 | 09-21-2023 |
| $2.62 | $2.65 | $2.62 | $2.68 | $2.6 | 223,421 | 09-20-2023 |
| $2.65 | $2.64 | $2.65 | $2.785 | $2.58 | 902,193 | 09-19-2023 |
| $2.62 | $2.49 | $2.62 | $2.64 | $2.43 | 1,234,765 | 09-18-2023 |
| $2.53 | $2.13 | $2.53 | $2.54 | $2.13 | 1,223,054 | 09-15-2023 |
| $2.13 | $2.18 | $2.13 | $2.23 | $2.1101 | 245,998 | 09-14-2023 |
| $2.14 | $2.21 | $2.14 | $2.22 | $2.12 | 289,506 | 09-13-2023 |
| $2.26 | $2.31 | $2.26 | $2.37 | $2.24 | 289,133 | 09-12-2023 |
| $2.36 | $2.39 | $2.36 | $2.5 | $2.32 | 189,391 | 09-11-2023 |
| $2.37 | $2.37 | $2.37 | $2.39 | $2.25 | 314,094 | 09-08-2023 |
| $2.38 | $2.49 | $2.38 | $2.49 | $2.31 | 191,725 | 09-07-2023 |
| $2.48 | $2.74 | $2.48 | $2.74 | $2.47 | 343,027 | 09-06-2023 |
| $2.68 | $2.89 | $2.68 | $2.91 | $2.67 | 179,644 | 09-05-2023 |
| $2.91 | $2.76 | $2.91 | $2.92 | $2.76 | 163,320 | 09-04-2023 |
| $2.91 | $2.76 | $2.91 | $2.92 | $2.76 | 163,320 | 09-01-2023 |
| $2.75 | $2.85 | $2.75 | $2.85 | $2.73 | 142,148 | 08-31-2023 |
| $2.8 | $2.99 | $2.8 | $2.99 | $2.79 | 117,803 | 08-30-2023 |
| $2.94 | $2.95 | $2.94 | $3 | $2.91 | 94,563 | 08-29-2023 |
| $2.98 | $2.85 | $2.98 | $2.9975 | $2.825 | 204,079 | 08-28-2023 |
Annexon Inc. Company Name:
ANNX Stock Symbol:
NASDAQ Market:
Ad
-
ANNX - Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference | Benzinga
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new cl...
-
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today anno...
-
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment i...